Dicer­na's RNAi drug shows 'in­con­sis­ten­t' re­sults in rare kid­ney dis­ease, tank­ing shares de­spite tri­al win

Some­times even when you win, you lose.

Dicer­na’s ne­dosir­an, an RNAi ther­a­peu­tic be­ing test­ed in pa­tients with a rare kid­ney dis­ease known as pri­ma­ry hy­per­ox­aluria …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER